MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-14-2024
T2 Biosystems Total Current Liabilities 2011-2026 | TTOO
Annual Total Current Liabilities T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.2 M | 10.1 M | 11.7 M | 9.8 M | 60.6 M | 52.3 M | 51.8 M | 9.88 M | 12.3 M | 5.17 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 60.6 M | 5.17 M | 28 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
160 M | $ 8.91 | 0.51 % | $ 594 M | USA |
 |
Castle Biosciences
CSTL
|
49.4 M | $ 25.85 | 0.08 % | $ 718 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
2.14 B | $ 67.92 | 2.38 % | $ 26.5 B | USA |
 |
Charles River Laboratories International
CRL
|
1.12 B | $ 157.08 | 3.45 % | $ 7.79 B | USA |
 |
CareDx, Inc
CDNA
|
89.8 M | $ 17.51 | 1.07 % | $ 933 M | USA |
 |
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
641 M | $ 103.81 | -0.04 % | $ 19.6 B | USA |
 |
Guardant Health
GH
|
303 M | $ 87.36 | 0.2 % | $ 11 B | USA |
 |
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Fulgent Genetics
FLGT
|
72.9 M | $ 15.45 | 3.34 % | $ 467 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
14.3 M | $ 17.14 | -0.87 % | $ 2.22 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.8 B | $ 100.87 | 3.33 % | $ 8.32 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
1.97 M | $ 2.86 | 0.7 % | $ 92.8 K | USA |
 |
IQVIA Holdings
IQV
|
8.34 B | $ 170.64 | 3.54 % | $ 29.3 B | USA |
 |
Danaher Corporation
DHR
|
6.81 B | $ 196.09 | 2.46 % | $ 140 B | USA |
 |
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.55 B | $ 120.51 | 1.03 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 199.89 | 0.48 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
544 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.71 B | $ 114.44 | 2.33 % | $ 34.8 B | USA |
 |
BioNano Genomics
BNGO
|
37.3 M | $ 1.11 | -0.45 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
12.5 M | $ 8.74 | 3.8 % | $ 248 M |  Israel |
 |
Neogen Corporation
NEOG
|
174 M | $ 9.31 | 2.2 % | $ 2.02 B | USA |
 |
Lantheus Holdings
LNTH
|
333 M | $ 78.85 | 0.45 % | $ 5.32 B | USA |
 |
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.39 | 1.84 % | $ 417 M | USA |
 |
Co-Diagnostics
CODX
|
5.75 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.34 B | $ 461.07 | 1.64 % | $ 13.3 B | USA |
 |
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
1.2 B | $ 1 224.83 | 2.14 % | $ 25.2 B |  Schweiz |
 |
Celcuity
CELC
|
31.7 M | $ 113.19 | -1.49 % | $ 4.47 B | USA |
 |
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
36.6 M | $ 18.02 | 3.56 % | $ 403 M | USA |
 |
NeoGenomics
NEO
|
88.3 M | $ 8.4 | 2.0 % | $ 1.08 B | USA |
 |
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
310 M | $ 201.85 | 2.11 % | $ 19.9 B | USA |
 |
OPKO Health
OPK
|
193 M | $ 1.2 | 0.84 % | $ 833 M | USA |